It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.
New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations / Harausz, Elizabeth P; Garcia-Prats, Anthony J.; Seddon, James A.; Schaaf, H. Simon; Hesseling, Anneke C.; Achar, Jay; Bernheimer, Jonathan; Cruz, Andrea T.; D'Ambrosio, Lia; Detjen, Anne; Graham, Stephen M.; Hughes, Jennifer; Jonckheere, Sylvie; Marais, Ben J.; Migliori, Giovanni Battista; Mckenna, Lindsay; Skrahina, Alena; Tadolini, Marina; Wilson, Peyton; Furin, Jennifer. - In: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. - ISSN 1073-449X. - ELETTRONICO. - 195:10(2017), pp. 1300-1310. [10.1164/rccm.201606-1227CI]
New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations
TADOLINI, MARINA;
2017
Abstract
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
